---
figid: PMC5480880__pone.0179510.g006
figlink: /pmc/articles/PMC5480880/figure/pone.0179510.g006/
number: F6
caption: MEKi treatment (B) reduces pERK levels and leads to increased cell death.
  In contrast, PI3K inhibition (C) initially reduces AKT signaling but this reduction
  leads to enhanced expression of RTKs including IR, IGFR1, EphA10, EphA7, ErbB2 and
  ErbB3 presumably through relief of inhibition of FOXO proteins. Increased expression
  of these RTKs leads to their increased activation (likely through receptor homo-
  or heterodimerization) which in turn, stimulates rebound activation of MEK-ERK pathway
  which in turn, enhances survival and development of resistance. Combined inhibition
  of PI3K and MEK (D) prevents rebound activation of ERK in response to PI3K single
  agent treatment and helps overcomes resistance.
pmcid: PMC5480880
papertitle: Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant
  KRAS as a treatment approach for peritoneal mucinous malignancies.
reftext: Murali R. Kuracha, et al. PLoS One. 2017;12(6):e0179510.
pmc_ranked_result_index: '48632'
pathway_score: 0.9673953
filename: pone.0179510.g006.jpg
figtitle: Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant
  KRAS as a treatment approach for peritoneal mucinous malignancies
year: '2017'
organisms:
- Mus musculus
- Moloney murine leukemia virus
- Homo sapiens
ndex: d676f27f-de9e-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5480880__pone.0179510.g006.html
  '@type': Dataset
  description: MEKi treatment (B) reduces pERK levels and leads to increased cell
    death. In contrast, PI3K inhibition (C) initially reduces AKT signaling but this
    reduction leads to enhanced expression of RTKs including IR, IGFR1, EphA10, EphA7,
    ErbB2 and ErbB3 presumably through relief of inhibition of FOXO proteins. Increased
    expression of these RTKs leads to their increased activation (likely through receptor
    homo- or heterodimerization) which in turn, stimulates rebound activation of MEK-ERK
    pathway which in turn, enhances survival and development of resistance. Combined
    inhibition of PI3K and MEK (D) prevents rebound activation of ERK in response
    to PI3K single agent treatment and helps overcomes resistance.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - EPHA7
  - THRA
  - EPHA10
  - MAP3K1
  - PIK3CA
  - MAPK3
  - ERBB3
  - MAPK1
  - SOS2
  - SOS1
  - SART3
  - CRB2
  - PIK3R5
  - PIK3R4
  - MAP2K1
  - PES1
  - CAST
  - BRAF
  - AKT2
  - MAP2K2
  - PIK3CD
  - PTEN
  - GRB2
  - PIK3R6
  - PIK3CB
  - FOXO3
  - KRAS
  - AKT3
  - PIK3R3
  - AKT1
  - PIK3CG
  - GDC0941
  - Cancer
  - Lung cancer
  - Noonan syndrome
genes:
- word: ErbB2,
  symbol: ERBB2
  source: hgnc_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: EphA7,
  symbol: EPHA7
  source: hgnc_symbol
  hgnc_symbol: EPHA7
  entrez: '2045'
- word: Erba
  symbol: ERBA
  source: hgnc_alias_symbol
  hgnc_symbol: THRA
  entrez: '7067'
- word: EphA10
  symbol: EPHA10
  source: hgnc_symbol
  hgnc_symbol: EPHA10
  entrez: '284656'
- word: MEKK
  symbol: MEKK
  source: hgnc_alias_symbol
  hgnc_symbol: MAP3K1
  entrez: '4214'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ErbB2,ErbB3
  symbol: ERBB3
  source: hgnc_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: p110
  symbol: p110
  source: hgnc_alias_symbol
  hgnc_symbol: SART3
  entrez: '9733'
- word: CRB2
  symbol: CRB2
  source: hgnc_symbol
  hgnc_symbol: CRB2
  entrez: '286204'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: pes
  symbol: PES
  source: hgnc_alias_symbol
  hgnc_symbol: PES1
  entrez: '23481'
- word: cast
  symbol: CAST
  source: hgnc_symbol
  hgnc_symbol: CAST
  entrez: '831'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: GRB2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: FOXO3A
  symbol: FOXO3A
  source: hgnc_prev_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
chemicals:
- word: GDC0941
  source: MESH
  identifier: C532162
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC5480880__F6
redirect_from: /figures/PMC5480880__F6
figtype: Figure
---
